[go: up one dir, main page]

MX2022006342A - Terapia combinada de cicloserina y litio para el tratamiento de la depresion. - Google Patents

Terapia combinada de cicloserina y litio para el tratamiento de la depresion.

Info

Publication number
MX2022006342A
MX2022006342A MX2022006342A MX2022006342A MX2022006342A MX 2022006342 A MX2022006342 A MX 2022006342A MX 2022006342 A MX2022006342 A MX 2022006342A MX 2022006342 A MX2022006342 A MX 2022006342A MX 2022006342 A MX2022006342 A MX 2022006342A
Authority
MX
Mexico
Prior art keywords
cycloserine
lithium
depression
treatment
combined therapy
Prior art date
Application number
MX2022006342A
Other languages
English (en)
Inventor
Yong Ha Chi
Sukchan Lee
Dong Cheol Jang
Gibeom Kwon
Original Assignee
Neurorive Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurorive Inc filed Critical Neurorive Inc
Publication of MX2022006342A publication Critical patent/MX2022006342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/1604—Lithium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a una terapia combinada de cicloserina y litio para la prevención o el tratamiento de la depresión. La administración combinada de cicloserina y litio según la presente invención tiene un efecto notablemente excelente de prevención o tratamiento de la depresión en comparación con cada administración individual, por lo tanto, se utiliza de manera eficaz como una terapia combinada para antidepresivos.
MX2022006342A 2019-11-27 2020-11-27 Terapia combinada de cicloserina y litio para el tratamiento de la depresion. MX2022006342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190154218 2019-11-27
PCT/KR2020/017101 WO2021107690A1 (en) 2019-11-27 2020-11-27 Combination therapy of cycloserine and lithium for the treatment of depression

Publications (1)

Publication Number Publication Date
MX2022006342A true MX2022006342A (es) 2022-08-11

Family

ID=76129568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006342A MX2022006342A (es) 2019-11-27 2020-11-27 Terapia combinada de cicloserina y litio para el tratamiento de la depresion.

Country Status (10)

Country Link
US (1) US12303530B2 (es)
EP (1) EP4065109A4 (es)
JP (1) JP7541765B2 (es)
KR (1) KR102287477B1 (es)
CN (1) CN114786668B (es)
AU (1) AU2020391291B2 (es)
BR (1) BR112022010280A2 (es)
CA (1) CA3154457C (es)
MX (1) MX2022006342A (es)
WO (1) WO2021107690A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
BRPI0711872A2 (pt) 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101596190A (zh) * 2009-07-07 2009-12-09 山东大学 D-环丝氨酸的制药用途
EP2538939A1 (en) 2010-02-24 2013-01-02 Universität Zürich Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
WO2011119227A2 (en) * 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
EP2670409B1 (en) 2011-01-31 2018-04-18 Serotech, LLC Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US20170304358A1 (en) * 2014-10-06 2017-10-26 Seyyed Nassir GHAEMI Primary and secondary prevention of dementias and suicide with trace dose lithium
DE102016111100A1 (de) 2016-06-17 2017-12-21 Knorr-Bremse Systeme für Schienenfahrzeuge GmbH Ventileinrichtung zur Leistungssteigerung mehrstufiger Verdichtereinheiten

Also Published As

Publication number Publication date
NZ787222A (en) 2025-07-25
CA3154457A1 (en) 2021-06-03
US12303530B2 (en) 2025-05-20
KR20210065892A (ko) 2021-06-04
JP2023501131A (ja) 2023-01-18
CN114786668B (zh) 2024-07-16
AU2020391291A1 (en) 2022-05-12
WO2021107690A1 (en) 2021-06-03
EP4065109A1 (en) 2022-10-05
CA3154457C (en) 2024-06-25
BR112022010280A2 (pt) 2022-08-16
JP7541765B2 (ja) 2024-08-29
US20220387481A1 (en) 2022-12-08
CN114786668A (zh) 2022-07-22
AU2020391291B2 (en) 2024-04-18
EP4065109A4 (en) 2023-09-13
KR102287477B1 (ko) 2021-08-09

Similar Documents

Publication Publication Date Title
CY1120950T1 (el) Θεραπεια ινωσης
MX387115B (es) Métodos para tratar la influenza.
PH12017502103A1 (en) Methods and kits for treating depression
EA201890201A1 (ru) Антибактериальные соединения
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
ECSP21053104A (es) Moduladores de la expresión de hsd17b13
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
EA202092748A1 (ru) Модуляторы экспрессии apol1
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2021001612A (es) Compuestos utiles en terapia del vih.
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
MX2018007048A (es) Composiciones para el cuidado bucal que comprenden al menos un copolimero de fosfato / acrilato y al menos un ingrediente activo cationico.
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
MX375924B (es) Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX2022003816A (es) Compuestos antibacterianos.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2022006342A (es) Terapia combinada de cicloserina y litio para el tratamiento de la depresion.